RT Journal Article
SR Electronic
T1 Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.17.20067348
DO 10.1101/2020.04.17.20067348
A1 Smyrlaki, Ioanna
A1 Ekman, Martin
A1 Lentini, Antonio
A1 Sousa, Nuno Rufino de
A1 Papanicolaou, Natali
A1 Vondracek, Martin
A1 Aarum, Johan
A1 Safari, Hamzah
A1 Muradrasoli, Shaman
A1 Rothfuchs, Antonio Gigliotti
A1 Albert, Jan
A1 Högberg, Björn
A1 Reinius, Björn
YR 2020
UL http://medrxiv.org/content/early/2020/08/05/2020.04.17.20067348.abstract
AB Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The most widely used method of COVID-19 diagnostics is a reverse transcription polymerase chain reaction (RT-PCR) assay, to detect the presence of SARS-CoV-2 RNA in patient samples, typically from nasopharyngeal swabs. RNA extraction is a major bottleneck in current COVID-19 testing, in terms of turn-around, logistics, component availability and cost, which delays or completely precludes COVID-19 diagnostics in many settings. Efforts to simplify the current methods are critical, as increased diagnostic availability and efficiency would benefit patient care and infection control. Here, we describe methods to circumvent RNA extraction in COVID-19 testing by performing RT-PCR directly on heat-inactivated subject samples as well as samples lysed with readily available detergents. Our data, including benchmarking with 597 clinically diagnosed patient samples against a standardised and sensitive diagnostic system, show that direct RT-PCR is a viable option to extraction-based COVID-19 diagnostics. Furthermore, using controlled amounts of active SARS-CoV-2, we evaluated performance of generic buffers as sample medium for the direct RT-PCR assay, identifying several suitable formulations. We also confirmed the effectiveness of heat inactivation of SARS-CoV-2 by plaque assay. Significant savings in terms of time and cost can be achieved by embracing RNA-extraction-free protocols, that feed directly into the established PCR-based testing pipeline. This could aid the expansion of COVID-19 testing.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols http://www.reiniuslab.com Funding StatementThis research was supported and funded by the SciLifeLab/KAW national COVID-19 research program project grant (2020.0182), the Swedish Research Council (2017-01723) and the Ragnar Soderberg Foundation to BR.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available.